Theravance Biopharma (TBPH) Net Margin (2013 - 2026)
Theravance Biopharma (TBPH) reported Net Margin of 28.08% for Q1 2026, up 6016.0% year-over-year from 0.46% in Q1 2025, and up 88.08% on a QoQ basis from 235.57% in Q4 2025.
Theravance Biopharma (TBPH) has 14 years of Net Margin data on file, last reported at 28.08% in Q1 2026.
- Quarterly Net Margin rose 6016.0% year-over-year to 28.08% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 6.09% (up 2344.0% YoY) and the FY2025 annual result came in at 186.85%, down 15988.0% from the prior year.
- Net Margin improved to 28.08% in Q1 2026 per TBPH's latest filing, from 235.57% in the prior quarter.
- Across five years, Net Margin topped out at 7445.92% in Q3 2022 and bottomed at 235.57% in Q4 2025.
- The 5-year median for Net Margin is 48.31% (2023), against an average of 444.74%.
- The widest annual swing landed in 2022, when Net Margin surged 728977 bps; it then slumped 750295 bps in 2023.
- Tracing TBPH's Net Margin over 5 years: stood at 26.58% in 2022, then slumped by 282 bps to 48.31% in 2023, then jumped by 360 bps to 125.46% in 2024, then sank by 288 bps to 235.57% in 2025, then jumped by 88 bps to 28.08% in 2026.
- Per Business Quant, the three latest TBPH Net Margin figures stand at 28.08% (Q1 2026), 235.57% (Q4 2025), and 18.06% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 0.82% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 34.53% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 20.17% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 17.65% |
| 10 | Theravance Biopharma | 823.54 Mn | 428.87 Mn | - | -28.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.08% |
| Dec 31, 2025 | -235.57% |
| Sep 30, 2025 | 18.06% |
| Jun 30, 2025 | 209.33% |
| Mar 31, 2025 | -88.24% |
| Dec 31, 2024 | 125.46% |
| Sep 30, 2024 | -75.28% |
| Jun 30, 2024 | -115.94% |
| Mar 31, 2024 | -80.42% |
| Dec 31, 2023 | -48.31% |
| Sep 30, 2023 | -57.03% |
| Jun 30, 2023 | -113.79% |
| Mar 31, 2023 | -212.04% |
| Dec 31, 2022 | 26.58% |
| Sep 30, 2022 | 7,445.92% |
| Jun 30, 2022 | 166.33% |
| Mar 31, 2022 | 623.68% |
| Dec 31, 2021 | 172.49% |
| Sep 30, 2021 | 156.15% |
| Jun 30, 2021 | 96.41% |
| Mar 31, 2021 | 47.77% |
| Dec 31, 2020 | -401.82% |
| Sep 30, 2020 | -403.37% |
| Jun 30, 2020 | -419.02% |
| Mar 31, 2020 | -5,536.87% |
| Dec 31, 2019 | -27.34% |
| Sep 30, 2019 | -470.19% |
| Jun 30, 2019 | -73.77% |
| Mar 31, 2019 | -1,359.69% |
| Dec 31, 2018 | -318.90% |
| Sep 30, 2018 | -462.95% |
| Jun 30, 2018 | -173.87% |
| Mar 31, 2018 | -782.39% |
| Dec 31, 2017 | -1,925.18% |
| Sep 30, 2017 | -1,564.37% |
| Jun 30, 2017 | -1,889.06% |
| Mar 31, 2017 | -2,115.94% |
| Dec 31, 2016 | -1,182.94% |
| Sep 30, 2016 | -178.04% |
| Jun 30, 2016 | -863.19% |
| Mar 31, 2016 | -228.95% |
| Dec 31, 2015 | -1,151.45% |
| Sep 30, 2015 | -442.27% |
| Jun 30, 2015 | -667.27% |
| Mar 31, 2015 | -208.20% |
| Dec 31, 2014 | -4,487.79% |
| Sep 30, 2014 | -860.09% |
| Jun 30, 2014 | -1,957.46% |
| Mar 31, 2014 | -6,351.11% |
| Dec 31, 2013 | -25,188.57% |
| Sep 30, 2013 | -171,158.33% |
| Jun 30, 2013 | -779,040.00% |
| Mar 31, 2013 | -146,245.45% |